Castle Biosciences
CSTL
197 hedge funds and large institutions have $706M invested in Castle Biosciences in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 67 increasing their positions, 65 reducing their positions, and 27 closing their positions.
272% more call options, than puts
Call options by funds: $3.7M | Put options by funds: $996K
48% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 27
6% more funds holding
Funds holding: 185 → 197 (+12)
1.54% more ownership
Funds ownership: 93.09% → 94.63% (+1.5%)
3% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 65
4% less capital invested
Capital invested by funds: $737M → $706M (-$30.5M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$23.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$22M |
| 3 |
Millennium Management
New York
|
+$12.4M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
+$7.67M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$7.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$15.7M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$14.6M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$12.5M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$11M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$9.58M |
CSTL Hedge Fund Activity: Q4 2024 in Review
197 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2024, worth a combined $706M — down 4.1% from $737M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CSTL positions and 27 closed out — a net gain of 13 holders — while 67 added to existing stakes and 65 trimmed.
The largest buyer was UBS Group, adding an estimated $23.1M. The largest seller was Bellevue Group, cutting an estimated $15.7M.
- 197 institutional investors held Castle Biosciences (CSTL) as of Q4 2024, up from 185 in Q3 2024.
- Funds reported $706M of Castle Biosciences stock for Q4 2024, down 4.1% quarter-over-quarter.
- 40 funds opened new Castle Biosciences positions in Q4 2024 and 27 closed out, a net change of +13 holders.
- The largest Castle Biosciences buyer in Q4 2024 was UBS Group, an estimated $23.1M added.
- The largest Castle Biosciences seller in Q4 2024 was Bellevue Group, an estimated $15.7M sold.
Based on aggregated 13F filings for Q4 2024.